Keyphrases
Cutaneous Leishmaniasis
92%
CD8+ T Cells
59%
Leishmania Braziliensis
53%
Neutrophils
23%
Leishmaniasis
22%
Cytolytic
19%
Immune Response
17%
Granzyme B
15%
Immunopathology
14%
Inflammatory Response
12%
Disease Severity
12%
Leishmania
12%
Skin Inflammation
11%
Saliva
11%
Cytotoxicity
10%
Interleukin-1β
10%
Mucocutaneous Leishmaniasis
9%
Macrophages
9%
Leishmania Parasites
9%
Salivary Gland
8%
Lutzomyia Intermedia
8%
Leishmania Major
8%
Stimulator of Interferon Genes (STING)
7%
NKG2D
7%
Gene Signature
7%
Cutaneous Lesions
7%
Inflammasome Activation
7%
Phenotypic Characteristics
7%
Functional Traits
7%
Inflammatory Environment
7%
Tofacitinib
7%
HLA-DR
7%
Hypoxia
7%
Host-directed Therapy
7%
Inflammation
7%
Monocytes
7%
T Cell Cytotoxicity
7%
Gene Expression
6%
Treatment Failure
6%
Leishmania Infection
6%
Infected Patients
6%
Skin Microbiome
5%
Pre-exposure
5%
Sand Fly
5%
Parasite Load
5%
Disease Outcome
5%
Balb C Mice
5%
Immunology and Microbiology
Cutaneous Leishmaniasis
100%
Cytotoxic T-Cell
61%
Leishmania braziliensis
43%
Leishmaniasis
39%
Immune Response
26%
Leishmania
24%
Neutrophil
24%
Granzyme B
15%
Immunopathology
13%
Inflammation Response
13%
Cytotoxicity
13%
Macrophage
13%
Dermatitis
13%
Interleukin-1
12%
Tumor Necrosis Factor
11%
Salivary Gland
9%
Lutzomyia
8%
Granulocyte
8%
Phlebotominae
8%
Leishmania Major
8%
Interferon-Stimulated Gene
7%
NKG2D
7%
Gene Expression
7%
HLA-DR
7%
Tofacitinib
7%
Inflammasome
7%
Gene Expression Assay
7%
T-Helper Cell
7%
T Cell-Mediated Cytotoxicity
7%
Parasite Load
7%
Bagg Albino Mouse
5%
Experimental Model
5%
Cytokine
5%